---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-059849"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:25:15.882120+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Carisma Therapeutics enters up to $100M ATM equity offering through Jefferies, replacing prior $97.8M capacity

## Summary
- May offer and sell common stock with aggregate offering price up to $100 million via Jefferies as sales agent.
- Commission of up to 3% of gross proceeds; Jefferies will use commercially reasonable efforts.
- A&R Sale Agreement replaces original 2019 agreement; prospectus supplement filed under effective shelf registration.
- Prior remaining capacity of ~$97.8M from earlier prospectus supplements is superseded.
- Company may suspend or terminate offering at any time; shares sold at market prices under Rule 415.

## SEC filing metadata
- accession: 0001104659-23-059849
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/0001104659-23-059849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/tm2315501d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-059849
- JSON: https://secwatch.observer/filing/0001104659-23-059849.json
- Plain text: https://secwatch.observer/filing/0001104659-23-059849.txt

## Key facts
- Material Agreements
  Carisma Therapeutics Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at up to $100.0 million (effective 2023-05-12).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $100.0 million
  - Effective: 2023-05-12
  source text: On May 12, 2023, Carisma Therapeutics Inc. (the “ Company ”), entered into an Amended and Restated Open Market Sale Agreement SM (the “ A&R Sale Agreement ”) with Jefferies LLC, as sales agent (“ Jefferies ”), pursuant to which the Company may offer and sell shares of its common stock, $0.001 par value per share (the “ Shares ”), from time to time through Jefferies. The Company has also filed a prospectus supplement (the “ Prospectus Supplement ”) under the Company’s universal shelf registration statement on Form S-3 (File No. 333-271295) that was originally filed with the Securities and Exchange Commission (the “ SEC ”) on April 17, 2023 and declared effective by the SEC on May 2, 2023 (the “ Registration Statement ”). Pursuant to the Prospectus Supplement, the Company may offer and sell Shares having an aggregate offering price of up to $100.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465923059849/0001104659-23-059849-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.